michaeldattoli
Michael Dattoli
Patients are treated by Michael Dattoli at the Dattoli Cancer Center and Brachytherapy Research Institute in Sarasota, Florida. He is a radiation therapy specialist who has become one of America's premier non-surgical cancer treatment experts. Dattoli uses brachytherapy, which is the use of a sealed radiation source in a specific location.
Dattoli developed an interest in pure sciences as a kid in Poughkeepsie, New York. While studying marine biology at the University of California, Berkeley, he wanted to find a way to use his scientific knowledge to help others. He returned to Poughkeepsie, excelled at Vassar College, and earned his medical degree in 1984 from Mount Sinai School of Medicine (now the Icahn School of Medicine at Mount Sinai).
Dattoli developed a significant interest in non-surgical cancer therapy options throughout his medical studies. He concentrated his efforts on developing treatment options for prostate cancer using brachytherapy after learning about achievements with other forms of cancer. Dr. Richard Sorace lured Dattoli away from Memorial Sloan Kettering Cancer Center more than 30 years ago, pushing the young doctor to go to Tampa and co-found a brachytherapy clinic.
26 posts
Don't wanna be here? Send us removal request.
Last Seen Blogs
casiocentre
casiocentre
cordialgargoyle
Meow~
sakura-chans-blog
Twisted Wonderland Request Blog!
veraciety-blog
TRUTH
Text
Global Market for Oncology Informatics - Current Business Trends
According to a new analysis from Grand View Research, the worldwide oncology informatics market is anticipated to expand at a CAGR of 5.7% between 2016 and 2030. This expansion is driven by the increase in cancer incidence rates, the rising expense of cancer treatment, and the trend toward fewer medical errors and hospital readmissions.
North America dominated the global market for oncology-related information in 2015. The market is driven by the increasing frequency of cancer in the region, advances in medical technology, and growing healthcare costs. Nonetheless, the industry faces a variety of restrictions. These disadvantages restrict the market's expansion.
The research evaluates current trends and forecasts future market growth. In addition, it provides information regarding the competitive landscape and critical product positioning. The research also examines the growth potential of various nations. For example, between 2020 and 2030, North America is anticipated to develop at the quickest rate, with a CAGR of XX%.
This market's expansion is hampered by several reasons, including a lack of skilled workers and ethical and legal restraints. Nonetheless, the incorporation of NGS technology into other research initiatives and the rise in cancer patients are anticipated to stimulate market growth.
By end-users, regions, and applications, the market is segmented. Each segment contains a market overview for the predicted period. The increasing incidence of cancer and the aim to reduce medical errors and readmission rates are driving the expansion of the Oncology informatics industry. However, various obstacles may impede the market's expansion. These obstacles include a lack of medical oncologists, the high cost of implementing devices, and data security concerns.
The market for Oncology informatics is moderately fragmented, with several regional competitors vying for market share. As a result, corporations have devised a range of corporate expansion tactics. Among these methods include investing in product development and maintaining competitive pricing. A significant example is a collaboration between Tempus and Precision Health Informatics to improve oncology precision medicine. These advancements are anticipated to support market expansion and generate profitable prospects for industry participants.
The COVID-19 pandemic has had multiple effects on the oncology informatics sector. It has affected the supply chain in numerous nations and slowed numerous procedures. Although supply was quickly restored, the pandemic presented cancer patients with distinct obstacles. For instance, patients were unable to access checkups and cancer medications. In addition, breast and colorectal cancer screening rates have dropped significantly.
The epidemic of COVID-19 has increased the financial strain on healthcare organizations. This has caused a change in how vendors interact with them. This new dynamic has given rise to intense competition among industry participants. Small start-ups are expanding their product lines and emerging as a competitive threat.
From 2020 to 2027, the Global Oncology Informatics Market is anticipated to expand at a moderate rate. This expansion results from rising healthcare expenses, cancer patients, and the increasing adoption of EHRs. The report comprehensively analyzes the market's key segments, drivers, and competitive landscape.
The oncology informatics market is booming due to increased cancer treatment costs, a growing patient population, and the increasing adoption of oncology-specific electronic health records (EHRs). However, concerns about data security and ineffective data integration are the industry's most significant obstacles. With sophisticated cancer informatics solutions, however, it is anticipated that these concerns will be reduced.
The primary segments of the Oncology Informatics Market are surgical oncology and radiation oncology. By 2021, the latter is anticipated to hold the highest market share. Increased electronic health record systems adoption will improve clinicians' work-life balance and increase productivity.
Between 2017 and 2023, the global oncology informatics market is anticipated to expand at a CAGR of 7.2%. This segment's growth is anticipated to be driven by new technologies and test kits. In addition, new market entrants may alter the competitive landscape. To obtain a competitive advantage, new players must concentrate on creating and integrating new technologies and decreasing operational complexity and total costs. In contrast, existing businesses concentrate on product releases and talk with competitors to increase their market share. In such a circumstance, they may not receive the rewards of a successful product launch or financial gain.
In addition, the growing number of cancer patients and the aging of the global population are anticipated to fuel the expansion of this market. Additionally, the adoption of electronic health records and rising investments in life sciences R&D activities are anticipated to contribute to the expansion of this market.
5 notes
·
View notes
Link
0 notes
Link
0 notes
Text
Current Research Directions in Radiation Oncology
Radiation oncology is a fast developing subject that is essential to cancer treatment. Innovations and increasing treatment methods are fueled by quick advancements in enhanced imaging tools and a better knowledge of cancer biology. Radiation oncologists may now design more patient-centric treatments and make greater use of available resources and technologies because of these developments.
Between 2010 and 2020, it's anticipated that there will be a sharp rise in the number of cancer patients and that there will be an increase in the number of radiation oncology experts from the current 140 to 280. However, the demand for radiation oncology treatment will grow faster than the number of physicians who can meet it. Therefore, more research must be done to enhance the availability of radiation oncologists and therapeutic services to fulfill the growing demand.
Symptom relief is the aim of radiation treatment. Radiotherapy has been used to treat cancer symptoms since the late 1800s. Radiation has become a very successful palliative strategy thanks to advancements in radiotherapy delivery and dose in the 20th century. Palliative radiation oncology is a specialization with specific regulations today. Palliative radiation targets local tumor management, symptom alleviation, and maybe even a cure.
Radiotherapy includes tumor mapping as a crucial component. It aids in deciding where and how much radiation should be administered to the nearby tissues. The most effective mapping technique is 4D conformal radiation treatment, which uses a variety of imaging modalities. In doing so, the doctor can accurately define the target from various perspectives.
Another advancement in radiation oncology is the creation of novel radiopharmaceuticals. These medications can specifically target cancer cells, reducing unintended side effects and enhancing the efficacy of radiation therapy. Combining lutetium Lu 177-dotatate with triazine, a drug that stops cells from producing certain chemicals required for DNA repair, is one innovative and promising combination.
Proton beam radiation treatment targets the tumor using proton beams. These beams' photons reveal the tissue before and behind the tumor since they pass through the body. With this course of treatment, there is far reduced risk to nearby healthy tissue when radiation is applied to cancer. Additionally, it enables patients to get radiation at greater doses. It thus became one of the most well-liked forms of cancer patient therapy.
A radiation oncologist will assess the patient's health and choose the most appropriate course of treatment before starting radiation therapy. Determining the specific treatment location entails looking through the patient's medical history and the findings of earlier examinations. The radiation therapist then uses imaging scans to determine the precise positions of the radiation beams and the treatment field.
Radiation oncology has become significantly more productive because of new technology. For instance, several facilities now treat primary tumors that have progressed to lymph nodes with the exact extreme dosage. The largest consensus network, the National Comprehensive Cancer Network, has also changed its recommendations. These recommendations are based on the knowledge of cancer centers from all around the world. The question of whether or not to provide more significant dosages to larger tumor volumes is still up for discussion.
Before treatment, CT scans can lessen the radiation's effect on the nearby tissues. A radiation oncologist can move the patient to reduce harm to the healthy tissue during treatment with CT scans. The radiation oncologist may be able to refocus the radiation beam on the tumor using this approach.
Molecular radiotherapy is a crucial topic for investigation and advancement. The diagnosis and treatment phases of radiation are changing thanks to 3D printing. To enhance the quality and safety of 3D printed materials used in radiotherapy, much research is being done on 3D printable materials. Additionally, these materials may be pretty crucial in the treatment of patients. Radiation oncology is at a thrilling time right now.
A new therapy method called FLASH-RT lessens radiation harm to healthy tissues. In addition, this form of treatment is 400 times quicker than standard radiation. As a result, it could ultimately replace other radiation techniques as the main ones used in clinical settings. This method, for instance, has been applied to treat T-cell cutaneous lymphoma.
0 notes
Link
1 note
·
View note
Link
1 note
·
View note
Link
1 note
·
View note
Link
0 notes
Link
0 notes
Link
0 notes
Text
Report on the Global Radiation Oncology Market in 2022
A variety of factors, such as the increase in healthcare expenditures and the construction of healthcare infrastructure, are anticipated to fuel the growth of the worldwide radiation oncology market. The report also offers important geographical information, such as the presence of important businesses and goods. Additionally, it offers details on significant end users including Change Healthcare, Experian, and the Mayo Clinic. The price of the goods and services, the difficulty of the procedure, and the high cost of the radiation treatment devices are a few issues that can restrain the market's expansion.
The Global Radiation Oncology Market Overview Report offers a comprehensive analysis of the market, highlighting significant factors such as market drivers and restraints, product and application trends, and regional market studies. The competitive environment is also examined in the research, including past and present statistics, technological developments, and anticipated market trends. It also describes the top players in the worldwide radiation oncology market as well as industry trends, obstacles, and opportunities.
The research also examines market trends across several geographies, including revenue, sales, and consumption. The research also identifies the major market participants and provides information about them, such as financial statements and company biographies. This aids the sector in understanding regional competitiveness and making the best choices for growth. Considering that the worldwide radiation oncology market will continue to be competitive through 2027, growth over the next several years may be constrained.
By 2021, it is anticipated that the North American radiation oncology market would grow to $1.2 billion. High healthcare costs and the adoption of cutting-edge cancer treatments are blamed for this surge. Furthermore, it is anticipated that the presence of important companies in North America would support market expansion. In the upcoming years, this region is probably going to have the most growth. The expansion of radiation oncology throughout Asia and the Pacific is also highlighted in the paper.
The rising prevalence of cancer in Asia is anticipated to boost the expansion of the radiation oncology market. Although Asia has a lower incidence of cancer than other continents, the number of cases is predicted to rise. In the end, this will result in a quicker rate of growth for the radiation oncology industry. By 2022, the area will have a CAGR of around 6%. The research also identifies the market growth factors for radiation oncology.
The competitive environment of the radiotherapy industry is also highlighted in the research. Becton, Dickinson, and Company, Elekta AB, IBA (Ion Beam Applications SA), Eckert & Ziegler Group, Mevion Medical Systems Inc., and Siemens Healthineers are some of the major competitors in the market. The strength of suppliers and purchasers is also highlighted in the study. The legal and regulatory structure that oversees radiotherapy is also highlighted in the paper.
Radiation oncology goods and services are anticipated to dominate the market in North America in 2022, making up about half of the total. This expansion is anticipated to be aided by the area's strong healthcare system and qualified medical personnel. Furthermore, the industry's expansion is probably going to be aided by the existence of significant market players like Accuray Incorporated, Nordion Inc., and Varian Medical Systems. Additionally, a rising number of cancer patients is anticipated to further fuel the market.
Radiation Therapy Using External Beams: This market category is anticipated to have a sizable market share in 2020 and to produce $11,638.2 million in revenue by 2030. It makes use of high-energy radiation that is applied directly to the tumor and efficiently kills cancer cells while sparing healthy tissues. Depending on the patient's condition, photons, electrons, or protons are used in external beam radiation therapy. Additionally, it is more effective in eliminating aberrant cells, which reduces discomfort.
Technological Developments: Radiation oncology technology will keep developing in the future. The effectiveness and safety of radiation treatments will both be enhanced by the use of new technology. Technological developments will speed up the market even further. For instance, 4D radiotherapy enables medical professionals to give conformal radiation, account for the movement of the organ, and follow the tumor in real-time. Furthermore, individuals with complex disorders, which are difficult to treat with traditional therapies, might benefit from modern therapeutic approaches.
0 notes
Link
0 notes
Link
0 notes
